StreetInsider.com News Articles

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than $1

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

Thu, 23 Jul 2026 06:00:00 -0400

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities

Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.

The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

Fri, 17 Jul 2026 06:01:00 -0400

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.

The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p<0.0001), as assessed by an independent review committee.

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

Tue, 30 Jun 2026 06:00:40 -0400

The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab,

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Tue, 30 Jun 2026 06:00:00 -0400

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS

MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions

Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Tue, 30 Jun 2026 06:00:00 -0400

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS

MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions

Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Tue, 30 Jun 2026 06:00:00 -0400

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS

MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions

Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology